Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (27): 5081-5086.doi: 10.3969/j.issn.2095-4344.2012.27.027

Previous Articles     Next Articles

Autologous bone marrow mesenchymal stem cells for myocardial renewal and repair

Xiao Wen-tao1, Gao Chuan-yu1, Dai Guo-you2, Li Mu-wei1, Wang Xian-pei1, Liu Hong-zhi1, Qi Da-tun1   

  1. 1Department of Cardiology, 2Central Laboratory, People’s Hospital of Zhengzhou University, Zhengzhou 450003, Henan Province, China
  • Received:2012-01-01 Revised:2012-01-01 Online:2012-07-01 Published:2013-11-01
  • Contact: Gao Chuan-yu, M.D., Chief physician, Doctoral supervisor, Department of Cardiology, People’s Hospital of Zhengzhou University, Zhengzhou 450003, Henan Province, China Gaocy2000@yahoo.com.cn
  • About author:Xiao Wen-tao★, Studying for master’s degree, Department of Cardiology, People’s Hospital of Zhengzhou University, Zhengzhou 450003, Henan Province, China xiaowt@163.com

PDF

458

Abstract:

BACKGROUND: Current clinical trials of stem cell transplantation focus on the research field of myocardial infarction. Few studies are about primary cardiomyopathy, and there have been no reports describing the comparison between myocardial infarction and primary cardiomyopathy.
OBJECTIVE: To assess the efficacy and safety of intracoronary transplantation of autologous bone marrow mesenchymal stem cells for treatment of non-functional myocardium caused by ischemic or non-ischemic diseases.
METHODS: 38 patients who underwent selective percutaneous coronary intervention due to myocardial infaction were divided into trial A group and control A group randomly. 36 patients with dilated cardiomyopathy were divided into trial B group and control B group randomly. Equal amounts of normal saline or bone marrow mesenchymal stem cells were infused into corresponding coronary artery through the guiding catheter post-operation in control groups and trial groups respectively.
RESULTS AND CONCLUSION: At 1 month after transplantation, compared with prior to transplantation and control groups, only left ventricular ejection fraction in the trial groups increased significantly (P < 0.05). At 3 months after transplantation, compared with prior to transplantation and control groups, the left ventricular ejection fraction in the trial groups increased significantly while myocardial perfusion defects in the trial groups were significantly reduced (P < 0.05); however, at this time point, there was significant difference in the left ventricular ejection fraction between trial groups (P < 0.05); the left ventricular end-diastolic diameter in the trial A group decreased significantly compared with prior to transplantation, control A group and trial B group (P < 0.05), while the trail B group showed significantly decreased left ventricular end-diastolic diameter only compared with prior to transplantation (P < 0.05). There was no significant difference in incidence of malignant cardiovascular events between trail groups and control groups during follow-up period (P > 0.05). Intracoronary transplantation of bone marrow mesenchymal stem cells is safe and effective in renewal and repair of non-functional myocardium and its efficacy in acute myocardial infarction patients is better than dilated cardiomyopathy patients.

CLC Number: